805,000 Shares in Abivax SA Sponsored ADR $ABVX Bought by Farallon Capital Management LLC

Key Points

• Farallon Capital Management bought a new position of 805,000 shares of Abivax (NASDAQ:ABVX) in Q3, valued at approximately $68.34 million, representing about 1.03% ownership.
• Several large institutions also piled in—UBS boosted its position to 4,461,262 shares (~$378.8M) and Darwin, Baker Bros., Fairmount and Jefferies initiated sizable stakes—leaving hedge funds and other institutions with roughly 47.91% of the stock.
• Analyst sentiment is mixed-to-positive with a consensus "Moderate Buy" and an average target of $134.75, while the stock trades around $115.50 and the company remains unprofitable (analysts forecast about -2.83 EPS for the year).

Farallon Capital Management LLC bought a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 805,000 shares of the company's stock, valued at approximately $68,344,000. Farallon Capital Management LLC owned 1.03% of Abivax as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ABVX. UBS Group AG boosted its position in shares of Abivax by 2,561.0% in the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company's stock valued at $378,761,000 after purchasing an additional 4,293,606 shares during the period. Darwin Global Management Ltd. acquired a new stake in Abivax during the 3rd quarter worth about $263,698,000. Baker BROS. Advisors LP acquired a new stake in Abivax during the 3rd quarter worth about $74,355,000. Fairmount Funds Management LLC purchased a new stake in Abivax during the third quarter valued at about $60,571,000. Finally, Jefferies Financial Group Inc. purchased a new stake in Abivax during the third quarter valued at about $38,827,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ABVX has been the subject of several recent analyst reports. Wedbush initiated coverage on shares of Abivax in a report on Tuesday, February 24th. They issued an "outperform" rating and a $110.00 target price for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Abivax in a report on Wednesday, January 21st. Truist Financial set a $140.00 price target on shares of Abivax in a research report on Monday, November 24th. Citigroup reiterated a "market outperform" rating on shares of Abivax in a research report on Thursday, January 8th. Finally, Piper Sandler reissued an "overweight" rating and set a $142.00 target price on shares of Abivax in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $134.75.

Abivax Trading Down 1.3%

Shares of NASDAQ ABVX opened at $115.50 on Monday. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. Abivax SA Sponsored ADR has a one year low of $4.77 and a one year high of $148.83. The business has a 50-day moving average price of $118.99 and a two-hundred day moving average price of $109.10. The firm has a market capitalization of $9.13 billion, a PE ratio of -27.63 and a beta of 1.01.

Abivax (NASDAQ:ABVX - Get Free Report) last issued its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The firm had revenue of ($4.92) million during the quarter. As a group, analysts predict that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

Want to see what other hedge funds are holding ABVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.